Temporal Associations Between Smoking and Cardiovascular Disease, 1971 to 2006 (from the Framingham Heart Study)

https://doi.org/10.1016/j.amjcard.2017.07.087Get rights and content

Smoking has consistently been related to cardiovascular risk. Public health efforts have yielded reduced smoking prevalence and gains in cardiovascular disease (CVD) prevention. We hypothesized that the contribution of tobacco to CVD risk would be attenuated over prospective decades (1971 to 2006) in a community-based cohort. We evaluated 5,041 Framingham Heart Study Offspring Cohort participants (mean age 36.1 years, 52% women) without prevalent CVD. We collected prospective data on smoking status, relevant CVD risk factors, and incident CVD events across prospective decades. We used multivariable-adjusted, Cox proportional hazard models to measure the effect of smoking on incident CVD over 3 prospective 12-year follow-up periods. Our results demonstrated a consistent twofold increased risk of CVD in men who smoke compared with nonsmokers for each 12-year time period spanning from 1971 to 2006. Women who smoked had a 1.5-fold increased CVD risk. Smoking remains an important risk factor despite substantial improvements in the prevention and treatment of CVD. Significant, contemporary improvements in CVD prevention—such as gains in hypertension and cholesterol treatment—have not attenuated the strong and persistent associations between smoking and CVD observed here. In conclusion, our results highlight the importance of continued public health efforts to address smoking as a modifiable exposure that strongly contributes toward CVD risk.

Section snippets

Methods

The Framingham Heart Study began in 1948 with the enrollment of the Original Cohort to study the epidemiology of CVD and its associated risk factors.6 In 1971, 5,124 children of the Original Cohort and their spouses were enrolled in what was termed the Offspring Cohort. Offspring Cohort participants have had successive examinations with medical history updates and health assessments every 4 to 8 years.7 The present analysis employs data from the enrollment (1971 to 1975) and from the third

Results

After excluding participants with a history of prevalent CVD (n = 83), the analysis consisted of 5,041 subjects participating in the enrollment examination (1971 to 1975). Descriptive data of participants from the 3 examinations are summarized in Table 1. At examination 1, the mean age was 36.1 years, 52% were women, and the mean BMI was 25.1 kg/m2. At this initial examination, 44.4% of the participants were classified as smokers, 1.8% had diabetes, and 3% were being treated for hypertension.

Discussion

We found that the association between smoking and CVD incidence was consistent over the 3-decade observation period. The finding was contrary to our initial hypothesis, as we expected that the vast improvements in primary prevention and risk factor modification over this period would attenuate the known relations of smoking with CVD. Our analysis, also accounting for hypertension and dyslipidemia treatment, found that smoking was consistently associated with an increased risk of CVD across

Disclosures

The authors have no conflicts of interest to disclose.

References (21)

There are more references available in the full text version of this article.

Cited by (29)

  • Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study

    2022, The Lancet
    Citation Excerpt :

    By contrast, a case-control study of 1·1 million homes in India reported similar risk ratios of death due to heart disease in women (1·7 [95% CI 1·3–2·1]) and in men (1·6 [1·5–1·8]).31 Furthermore, data from the Framingham Heart Study Offspring Cohort32 showed consistently larger HRs in men who smoked than in women who smoked over a 30 year observation period (1976–2006). We recently reported that smokers in high-income countries started smoking at younger ages and smoked more products per day and for a longer duration than smokers in middle-income and low-income countries.16

  • Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies

    2019, Journal of Clinical Lipidology
    Citation Excerpt :

    In our analysis, there was no suggestion of higher levels of PCSK9 among participants with vs without hypertension. Tobacco smoking is related to increased CVD risk and remains an important risk factor despite substantial improvements in the prevention and treatment of CVD.37,38 Smokers experience CVD events much earlier than nonsmokers,38 as illustrated in our study in which smokers were younger than nonsmokers.

View all citing articles on Scopus

See page 1790 for disclosure information.

This work was supported by the National Institutes of Health/National Heart, Lung, and Blood Institute contracts N01-HC-25195 and HHSN268201500001I from the National Heart, Lung, and Blood Institute's Framingham Heart Study and by Grant 2015084 from the Doris Duke Charitable Foundation.

View full text